{
    "clinical_study": {
        "@rank": "100762", 
        "arm_group": [
            {
                "arm_group_label": "Amosartan\u00ae tab", 
                "arm_group_type": "Experimental", 
                "description": "Amlodipine 5mg /Losartan 100mg"
            }, 
            {
                "arm_group_label": "Cozaar\u00ae plus pro tab", 
                "arm_group_type": "Active Comparator", 
                "description": "Losartan 100mg/ HCTZ 12.5mg"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to evaluate the blood pressure lowering effects of an\n      amlodipine/losartan combination treatment and losartan/Hydrochlorothiazide combination\n      treatment in patients with essential hypertension uncontrolled with losartan 100mg\n      monotherapy."
        }, 
        "brief_title": "The Efficacy and Safety Study of Anti-hypertension Combination Drug in Patients Uncontrolled With Monotherapy.", 
        "completion_date": {
            "#text": "January 2013", 
            "@type": "Actual"
        }, 
        "condition": "Hypertension", 
        "condition_browse": {
            "mesh_term": "Hypertension"
        }, 
        "detailed_description": {
            "textblock": "-  Quality assurance plan was implemented by site monitoring, including data validation\n           and registry procedures and Source data verification to assess the accuracy,\n           completeness by comparing the data to external data sources (medical records and paper\n           case report forms).\n\n        -  Data dictionary contains the registry, including the source of the variable, coding\n           information (MedDRA ver12.0), and normal ranges.\n\n        -  Statistical analysis were performed using SAS\u00ae Version 9.2, SAS institute, Cary, NC,\n           USA"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  20 aged or over\n\n          -  Patients with blood pressure measured at Visit 1; 90mmHg\u2264MSDBP mmHg if on\n             anti-hypertensive drugs, 95mmHg\u2264MSDBP mmHg if not on anti-hypertensive drugs\n\n          -  Patients with blood pressure measured at Visit 2 were 90mmHg\u2264MSDBP mmHg\n             (non-responder to Losartan 100mg for 4-week treatment)\n\n        Exclusion Criteria:\n\n          -  Patients with too high Blood pressure\n\n             \u2022\u2265 sitSBP 20mmHg or \u2265 sitDBP 10mmHg of variation in three measurements from the\n             reference arm selected at Screening\n\n          -  History of hypersensitivity to CCB ,Angiotensin II receptor blockers or Sulfonamide.\n\n          -  Secondary hypertension or suspected to be"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "199", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "April 7, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01828359", 
            "org_study_id": "HM-ALOS-401"
        }, 
        "intervention": [
            {
                "arm_group_label": "Amosartan\u00ae tab", 
                "description": "comparison of different combination of anti-hypertension drug", 
                "intervention_name": "Amosartan\u00ae tab", 
                "intervention_type": "Drug", 
                "other_name": "Amlodipine 5mg /Losartan 100mg"
            }, 
            {
                "arm_group_label": "Cozaar\u00ae plus pro tab", 
                "description": "comparison of different combination of anti-hypertension drug", 
                "intervention_name": "Cozaar\u00ae plus pro tab", 
                "intervention_type": "Drug", 
                "other_name": "Losartan 100mg/ HCTZ 12.5mg"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Amlodipine", 
                "Losartan"
            ]
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "April 9, 2013", 
        "number_of_arms": "2", 
        "official_title": "An Eight-week, Randomized, Double-blind Multicenter Study to Compare the Efficacy and Safety of Amosartan\u00ae Tab 5/100mg Versus Cozaar\u00ae Plus Pro Tab in Patients With Essential Hypertension Uncontrolled With Losartan 100mg Monotherapy", 
        "overall_official": {
            "affiliation": "Gachon University Gil Medical Center", 
            "last_name": "Taehoon Ahn, Ph.D.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "South Korea: Korea Food and Drug Administration (KFDA)", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "January 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Change from baseline in Mean Sitting Diastolic Blood Pressure (MSDBP)", 
            "safety_issue": "No", 
            "time_frame": "Baseline, Week 8"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01828359"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Change from baseline in MSDBP", 
                "safety_issue": "No", 
                "time_frame": "Baseline, week 4"
            }, 
            {
                "measure": "Change from baseline Mean Seated Systolic Blood Pressure (MSSBP)", 
                "safety_issue": "No", 
                "time_frame": "Baseline, Week 4 and 8"
            }, 
            {
                "description": "Rate of patients who achieved target blood pressure (MSSBP < 140 mmHg and MSDBP < 90 mmHg), or MSSBP decrease > 20 mmHg from baseline or MSDBP decrease > 10 mmHg from baseline.", 
                "measure": "Blood pressure responder rate", 
                "safety_issue": "No", 
                "time_frame": "Baseline, Week 4 and 8"
            }
        ], 
        "source": "Hanmi Pharmaceutical Company Limited", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Hanmi Pharmaceutical Company Limited", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "August 2010", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2013"
    }
}